MedinCell S.A. is a pharmaceutical company that develops a portfbuy
stock in good hands
sl 4.5
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.02EUR
−32.01 MEUR
9.89 MEUR
20.69 M
About MEDINCELL S.A.
Sector
CEO
Christophe Douat
Headquarters
Jacou
Website
Employees (FY)
143
Founded
2002
ISIN
FR0004065605
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. It focuses on combining its proprietary BEPO technology with active ingredients already known and marketed; it controls the regular delivery of a drug at the optimal therapeutic dose. The company was founded by Anh Nguyen and Christophe Douat on January 9, 2003 and is headquartered in Jacou, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MEB is 14.16 EUR — it has increased by 2.91% in the past 24 hours. Watch MEDINCELL SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange MEDINCELL SA stocks are traded under the ticker MEB.
MEB stock has fallen by 8.41% compared to the previous week, the month change is a 24.87% rise, over the last year MEDINCELL SA has showed a 108.24% increase.
We've gathered analysts' opinions on MEDINCELL SA future price: according to them, MEB price has a max estimate of 22.00 EUR and a min estimate of 14.00 EUR. Watch MEB chart and read a more detailed MEDINCELL SA stock forecast: see what analysts think of MEDINCELL SA and suggest that you do with its stocks.
MEB stock is 3.66% volatile and has beta coefficient of 0.51. Track MEDINCELL SA stock price on the chart and check out the list of the most volatile stocks — is MEDINCELL SA there?
Today MEDINCELL SA has the market capitalization of 412.37 M, it has increased by 3.62% over the last week.
Yes, you can track MEDINCELL SA financials in yearly and quarterly reports right on TradingView.
MEDINCELL SA is going to release the next earnings report on Jun 25, 2024. Keep track of upcoming events with our Earnings Calendar.
MEB net income for the last quarter is −8.16 M EUR, while the quarter before that showed −18.26 M EUR of net income which accounts for 55.33% change. Track more MEDINCELL SA financial stats to get the full picture.
No, MEB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 19, 2024, the company has 143.00 employees. See our rating of the largest employees — is MEDINCELL SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDINCELL SA EBITDA is −22.95 M EUR, and current EBITDA margin is −264.66%. See more stats in MEDINCELL SA financial statements.
Like other stocks, MEB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDINCELL SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDINCELL SA technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDINCELL SA stock shows the buy signal. See more of MEDINCELL SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.